A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Zhu, Min; Wang, Huixue; Liu, Jiyong; He, Hailong; Hua, Xuguo; He, Qianjun; Zhang, Lingxia; Ye, Xiaojian; Shi, Jianlin

doi:10.1016/j.biomaterials.2010.11.025

Cited by 93 publications

(51 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,[68][69][70] As already noted, PLGA has received attention as a foundation component of microparticles for anti-TB drug delivery into the lungs. However, the acidification of degrading PLGA microspheres entrenched in the cavities of defective bone may provoke a considerable lowering of pH, 59,60,68 which could result in drug-resistant TB.…”

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 93%

“…Hence, any tuberculosis bacteria existing at the osseous focal point or which survive after the removal of the infected tissues by operation are hard to entirely eliminate with standard methods of treatment; any such remaining bacteria can easily turn into dormant bacillus and will replicate quickly once in a comorbid environment. 68 Another general regulation in the area of osteoarticular tuberculosis treatment has been surgical involvement. 69,70 Due to advancements in fixation equipment and technology, surgery on the bone disease foci is recommended.…”

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

“…An implantable antitubercular amalgamated scaffold DDS with mesoporous silica nanoparticles and bioactive glass coated in a β-TCP bioceramic as temporary holding material was fabricated by Zhu et al 68 The complex system was reported to show greater rifampin and isoniazid encapsulation capability than a pure β-TCP scaffold. In comparison to the complete in vitro release of all drugs in 72 hours from a pure β-TCP scaffold, this composite-scaffold DDS (CS-DDS) astonishingly demonstrated the controlled co-discharge of isoniazid and rifampin for over a month.…”

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

“…The therapeutic quantity of both isoniazid and rifampin for treating TB in vivo can be sustained for an extended period over 6 weeks with no major long-term lesions to the liver and kidneys. 68 This kind of approach suggests future innovative uses for the material, containing antibacterial agents, used for temporary holding, which can release drugs over a long period. It has potential not only in the treatment of TB but also when tailored for application in bone replacement surgeries to avoid internal infection and post-surgery complications.…”

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

See 3 more Smart Citations

Controlled-release approaches towards the chemotherapy of tuberculosis

Saifullah

Hussein

Ali³

2012

IJN

View full text Add to dashboard Cite

Tuberculosis (TB), caused by the bacteria Mycobacterium tuberculosis, is notorious for its lethality to humans. Despite technological advances, the tubercle bacillus continues to threaten humans. According to the World Health Organization's 2011 global report on TB, 8.8 million cases of TB were reported in 2010, with a loss of 1.7 million human lives. As drugsusceptible TB requires long-term treatment of between 6 and 9 months, patient noncompliance remains the most important reason for treatment failure. For multidrug-resistant TB, patients must take second-line anti-TB drugs for 18-24 months and many adverse effects are associated with these drugs. Drug-delivery systems (DDSs) seem to be the most promising option for advancement in the treatment of TB. DDSs reduce the adverse effects of drugs and their dosing frequency as well as shorten the treatment period, and hence improve patient compliance. Further advantages of these systems are that they target the disease area, release the drugs in a sustained manner, and are biocompatible. In addition, targeted delivery systems may be useful in dealing with extensively drug-resistant TB because many side effects are associated with the drugs used to cure the disease. In this paper, we discuss the DDSs developed for the targeted and slow delivery of anti-TB drugs and their possible advantages and disadvantages.

show abstract

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 93%

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

Section: Chitosan-montmorillonite (Mmt) Hydrogelmentioning

confidence: 99%

See 2 more Smart Citations

Controlled-release approaches towards the chemotherapy of tuberculosis

Saifullah

Hussein

Ali³

2012

IJN

View full text Add to dashboard Cite

show abstract

“…The best concentrations of drugs (INH and RFP) for treating tuberculosis (TB) in-vivo can be maintained for an extra-long duration over 42 days without significant longterm lesions to liver and kidney [135].…”

Section: Scaffolds With Extra-functionalities Such As Drug Release Abmentioning

confidence: 99%

Bioceramic Scaffolds

Amin¹,

Ewais²

2017

Scaffolds in Tissue Engineering - Materials, Technologies and Clinical Applications

View full text Add to dashboard Cite

Millions of peoples in the world suffer from their bone damage tissues by disease or trauma. Every day, thousands of surgical procedures are performed to replace or repair these tissues. The availability of these tissues is a big problem, and their costs are expensive. The repair of these defects has become a major clinical and socioeconomic need with the increase of aging population and social development. The emerge of tissue engineering (TE) is considered as a glimmer of hope to contribute in solving this problem. It aims at the regeneration of damaged tissues with restoring and maintaining the function of human bone tissues using the combination of cell biology, materials science, and engineering principles. In this chapter, the current state of the tissue engineering in particular bioceramic scaffolds was discussed. Concept of tissue engineering was explored. Bioceramic scaffold materials, their processing techniques, challenges taken into consideration the design of the scaffolds, and their in-vitro and in-vivo studies were highlighted. The scaffolds with extra-functionalities such as drug release ability and clinical applications were mentioned.

show abstract

Silica, Amorphous

Gräf

2018

Kirk-Othmer Encyclopedia of Chemical Technology

View full text Add to dashboard Cite

Amorphous or noncrystalline silica is silicon dioxide ( SiO 2 ) that does not have a crystalline structure. Amorphous silica can be naturally occurring or synthetic, and has a wide range of applications. The chemical structure and chemical, physical, and particulate characteristics of amorphous silica are given. Polymerization processes and further modifications and important applications, including silica sols and colloidal silica, silica gel, precipitated silica, pyrogenic silica (fumed silica), and fused silica and fused quartz, are discussed. Formation, properties, processing, modification approaches, and applications of naturally occurring amorphous silica are presented as well. Finally, health effects and safety issues of amorphous silica materials are introduced, including exposure and uptake, biological effects, and classification and labeling according to international regulations.

show abstract

A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Cited by 93 publications

References 39 publications

Controlled-release approaches towards the chemotherapy of tuberculosis

Controlled-release approaches towards the chemotherapy of tuberculosis

Bioceramic Scaffolds

Silica, Amorphous

Contact Info

Product

Resources

About